Amlodipine decreased and Amlodipine•Besylate combination increased for treating hypertension over 6 year
Posted on July 23, 2020 09:36
Modified on July 23, 2020 09:47
[관련기사=6년간 고혈압약 처방 암로디핀 줄고, 암로디핀·발사르탄 복합제 늘고]
DOCTOR:GATE-prescription information provides the information over 6 years from 2013~2018 on frequently prescribed medication and market share of each disease
[MedigateNews] MediC&C, which runs the No.1 doctors’ community, Medigate, has opened a new data base service called Doctorgate (http://data.medigate.net/) for the medical professionals as well as its members.
What is the most prescribed drug for 'hypertension' in Korea? According to the 2018 statistics from the Health Insurance Review and Assessment Service, the number 1 treatment for hypertension was Amlodipine Besylate, which accounted for 10.5% of the total prescription, and there were a total of 117 products which were registered for reimbursement.The 2nd place was Losartan Potassium (Losartan Potassium, 141 reimbursed products), 3rd place was Amlodipine Besylate•Valsartan (100 reimbursed products).
Looking at the market share of the 1st, 2nd, and 3rd hypertension drugs over the past 6 years, amlodipine besylate decreased slightly from 11.1% in 2013 to 10.5% in 2018. Losartan potassium also decreased from 8.9% in 2013 to 7.6% in 2018. However, the Amlodipine Besylate•Valsartan combination increased from 1.7% in 2013 to 5.5% in 2018.
The Doctor:Gate-prescription information, which was first launched in July of the last year, is the service based on the de-identified clinical big data of the Health Insurance Review and Assessment Service. The prescription information, which had previously provided the prescription data for one year in 2017, was expanded its service to provide the trend of prescription changes over the last six years from 2013 to 2018.
The user can check the drug prescription pattern and market share ranking of the last 6 years by entering a simple Korean or English word of the disease or a disease code. In the detailed information section, statistics such as dose, specialty department, patient gender, patient age, hospital type, region, and number of beds can be found. The drug-related news or YouTube video can be found as well.
In addition, outpatient and inpatient prescriptions were categorized by separating the inpatient data set (HIRA-NIS) from the entire patient data set (HIRA-NPS) among the patient sample data provided by HIRA. If the drug was released after 2019 and has no prescription information data, you can find the method of administration, components, and released product names in the new drug category.
Any doctors or other medical professionals can use the Doctor:Gate-prescription information to check on the components and drug-related information of frequently prescribed drugs for each disease. The MEDI:GATE doctor members are additionally provided with the items such as doctors’ comments on the drug or the community posting information on the components that are shared in the drug component detail page. TheMediC&C was awarded with the Presidential Award in 2016 at the ‘4th Public Data Utilization Entrepreneurship Competition.’
By Sol Im